The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia.

MLA

Kapriniotis, Konstantinos, et al. “The Latest in Clinical Trial Results of 5-Alpha Reductase Inhibitors in Combination Regimens for Benign Prostatic Hyperplasia.” Expert Opinion on Pharmacotherapy, vol. 26, no. 3, Feb. 2025, pp. 301–11. EBSCOhost, https://doi.org/10.1080/14656566.2025.2453586.

APA

Kapriniotis, K., Manolitsis, I., Juliebo-Jones, P., Pietropaolo, A., Tsaturyan, A., Tonyali, S., Sener, E., Emiliani, E., Talyshinskii, A., Karagiotis, T., Somani, B., & Tzelves, L. (2025). The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy, 26(3), 301–311. https://doi.org/10.1080/14656566.2025.2453586

Chicago

Kapriniotis, Konstantinos, Ioannis Manolitsis, Patrick Juliebo-Jones, Amelia Pietropaolo, Arman Tsaturyan, Senol Tonyali, Emre Sener, et al. 2025. “The Latest in Clinical Trial Results of 5-Alpha Reductase Inhibitors in Combination Regimens for Benign Prostatic Hyperplasia.” Expert Opinion on Pharmacotherapy 26 (3): 301–11. doi:10.1080/14656566.2025.2453586.